An interventional study of routine nursing care group and TCM intervention group in Transitional Care Model, Coronary Heart Disease and Medication Adherence, sponsored by Qing Wang. Completed at 1 site in China. Open to participants aged 47 Years to 58 Years. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Qing Wang · Not applicable, Interventional, and Supportive care
Patients with coronary heart disease (CHD) require long-term medication and lifestyle modification following percutaneous coronary intervention (PCI). However, they often face challenges such as poor medication adherence and inadequate self-management. This study aims to evaluate the effects of the transitional care model (TCM) on CHD patients after PCI, regarding medication adherence, self-efficacy, and lipid levels.
TCM improved medication adherence, self-efficacy, and lipid profiles in CHD patients after PCI, while enhancing overall patient satisfaction. Compared with routine nursing care, TCM yielded superior clinical benefits and is recommended for broader application in the post-PCI management of CHD patients.
2,839 studies on the registry are indexed under Coronary Disease; 311 are open to participants now.
This study's enrollment of 108 is below the median of 124 across 1,583 interventional studies indexed under Coronary Disease.
Browse Coronary Disease studies →This is the only study on the registry with Qing Wang as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients assigned to the control group underwent routine nursing care based on the standardized medical treatment, including admission health education (PCI postoperative risk management and medication instructions), psychological counseling, dietary and exercise guidance, individualized rehabilitation planning, and discharge instructions. After discharge, patients attended routine outpatient follow-up visits, including laboratory testing of blood lipids, blood pressure, and blood glucose, without structured follow-up or WeChat-based education. Routine outpatient education and guidance were provided only.
Other: routine nursing care group
Patients in the observation group received a 3-month TCM intervention delivered by specially trained nurses, in addition to routine nursing care.
Other: TCM intervention group
Patients assigned to the control group underwent routine nursing care based on the standardized medical treatment, including admission health education (PCI postoperative risk management and medication instructions), psychological counseling, dietary and exercise guidance, individualized rehabilitation planning, and discharge instructions. After discharge, patients attended routine outpatient follow-up visits, including laboratory testing of blood lipids, blood pressure, and blood glucose, without structured follow-up or WeChat-based education. Routine outpatient education and guidance were provided only.
Patients in the observation group received a 3-month TCM intervention delivered by specially trained nurses, in addition to routine nursing care.
Medication Adherence
Medication adherence will be assessed using the Medication Adherence Report Scale-5 (MARS-5). The scale consists of 5 items that evaluate nonadherent behaviors (e.g., forgetting to take medications, altering dosages). Each item is scored on a 5-point Likert scale (1="always" to 5="never"), with total scores ranging from 5 to 25. A higher total score indicates better medication adherence.
Time frame: Baseline (before discharge) and 3 months after discharge
Self-efficacy
Self-efficacy will be assessed using the General Self-Efficacy Scale (GSS). The GSS is a validated 16-item instrument, with each item scored from 0 to 4. Higher total scores reflect greater self-efficacy in managing health and adhering to treatment recommendations.
Time frame: Baseline (before discharge) and 3 months after discharge
Lipid Profile
Fasting serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) will be measured using an automated biochemical analyzer. All measurements will be performed in mmol/L.
Time frame: Baseline (before discharge) and 3 months after discharge.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.